Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
August 4, 2023
Date of Patent:
April 9, 2024
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
July 1, 2022
Date of Patent:
November 22, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
June 30, 2022
Date of Patent:
November 8, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
June 29, 2022
Date of Patent:
October 25, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
April 11, 2022
Date of Patent:
September 27, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
September 13, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
March 11, 2022
Date of Patent:
August 16, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
March 1, 2022
Date of Patent:
June 7, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
October 22, 2021
Date of Patent:
April 5, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
April 5, 2022
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
March 29, 2021
Date of Patent:
September 21, 2021
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Type:
Grant
Filed:
November 25, 2020
Date of Patent:
April 27, 2021
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, José Luis Velada, Dominique Drouin
Abstract: The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.
Type:
Grant
Filed:
June 28, 2011
Date of Patent:
December 1, 2020
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drounin
Abstract: The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptive (“POC”), such as Drosphirenone.
Type:
Grant
Filed:
May 17, 2019
Date of Patent:
March 31, 2020
Assignee:
Laboratorios Leon Farma SA
Inventors:
Philippe Perrin, Jose Luis Velada, Dominique Drouin
Abstract: The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.
Type:
Application
Filed:
October 25, 2019
Publication date:
February 20, 2020
Applicant:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe PERRIN, Jose Luis VELADA, Dominique DROUIN
Abstract: The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptive (“POC”), such as Drosphirenone.
Type:
Application
Filed:
May 17, 2019
Publication date:
September 19, 2019
Applicant:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe PERRIN, Jose Luis VELADA, Dominique DROUIN
Abstract: The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.
Type:
Application
Filed:
May 17, 2019
Publication date:
September 5, 2019
Applicant:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe PERRIN, Jose Luis VELADA, Dominique DROUIN
Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
January 15, 2019
Assignee:
Laboratorios Leon Farma SA
Inventors:
Philippe Perrin, Dominique Drouin, Cecile Boyer-Joubert
Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.
Type:
Application
Filed:
February 15, 2017
Publication date:
August 3, 2017
Applicant:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe PERRIN, Dominique DROUIN, Cecile BOYER-JOUBERT
Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.
Type:
Grant
Filed:
June 23, 2015
Date of Patent:
March 28, 2017
Assignee:
LABORATORIOS LEON FARMA SA
Inventors:
Philippe Perrin, Dominique Drouin, Cécile Boyer-Joubert